Nice and Saclay, November 2025 AlgenScribe has announced the successful completion of an equity financing round, raising €470,000. This investment will support the ongoing development of its innovative platform, which integrates synergistic molecular biology tools designed to tackle multiple challenges in the field of gene editing. The company has entered into its first collaboration with an American foundation, marking a significant milestone. The new scientific program

Nice, le 07 janvier 2025. Fondée fin 2022, AlgenScribe se positionne sur le marché très dynamique de la médecine génomique avec la construction et le développement d’une plate-forme inédite d’édition du génome. La société adresse en priorité le défi de l’efficacité du remplacement de gène qui s’avère parfois insuffisante dans le domaine de la thérapie génique et pour des applications en oncologie. Pour surmonter la problématique de l’efficacité du remplacement de gène, c’est-

25 of July 2024   The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from France have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases. A special kind of German-French friendship is being fostered here: The Max Delbrück Center and the French biotech company AlgenScribe want to jointly further develop and improve thei

5 September 2023 ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement License allows AlgenScribe to expand its research...